Skip to main content

Pipeline

Advancing new treatment options for severe autoimmune diseases

Priovant is developing brepocitinib, a dual TYK2/JAK1 inhibitor administered as a once-daily oral therapy. Brepocitinib (LISRAYA) is approved for adults with dermatomyositis and is in late-stage clinical trials across multiple other indications with high unmet need.

Filter by phase
Priovant development pipeline
IndicationStage Status
Dermatomyositis (DM) Commercial LISRAYA (brepocitinib) was approved by FDA for treatment of adults with dermatomyositis in August 2026. Learn more here.
Non-infectious uveitis (NIU) Phase 3 Results from Phase 3 CLARITY study expected in the second half of 2026.
Cutaneous sarcoidosis (CS) Phase 3 Phase 3 BEACON+ study currently enrolling.
Lichen planopilaris (LPP) Phase 2/3 Phase 2/3 ALPINE study currently enrolling.
Indication
Preclinical Phase 1 Phase 2 Phase 3 Commercial

LISRAYA (brepocitinib) was approved by FDA for treatment of adults with dermatomyositis in August 2026. Learn more here.

Results from Phase 3 CLARITY study expected in the second half of 2026.

Phase 3 BEACON+ study currently enrolling.

Phase 2/3 ALPINE study currently enrolling.